Kras-targeting pill doubles survival in metastatic pancreatic cancer, experts say
TL;DR Summary
A daily pill called daraxonrasib doubled median survival in a 500-patient trial of metastatic pancreatic cancer, from about 6.5–6.7 months with chemotherapy to 13.2 months, and it had fewer side effects. The drug inhibits Kras, a common cancer driver, and experts call the results landscape-changing and potentially game-changing, though access to the drug remains a key challenge.
- Daily pill can double survival time for world’s deadliest cancer, trial shows The Guardian
- After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses NBC News
- Experimental pill promises new hope for deadly pancreatic cancer WBUR
- Revolution's pancreatic cancer drug doubles survival, boosts quality of life Reuters
- RevMed Drug Delays Painful Cancer Symptoms While Extending Life Bloomberg.com
Reading Insights
Total Reads
0
Unique Readers
16
Time Saved
3 min
vs 4 min read
Condensed
92%
724 → 57 words
Want the full story? Read the original article
Read on The Guardian